Patent Assignment
Reel/Frame 026561/0701
Security Agreement
Recorded: 2011-07-08
Received: 2011-07-08
Pages: 10
Assignor
PENWEST PHARMACEUTICALS CO.
Executed: 2011-06-17
Assignee
MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT
1 PIERREPONT PLAZA, BROOKLYN, NY, 11201, UNITED STATES
Covered Properties
(22)
Synthesis of Alpha-Tocopherolquinone Derivatives, and Methods of Using the Same
Application:
13/044,056 →
Chronotherapeutic Dosage Forms and Methods of Treatment Using Chronotherapy
Application:
12/985,137 →
Synthesis of Alpha-Tocopherolquinone Derivatives, and Methods of Using the Same
Application:
61/312,185 →
Chronotherapeutic dosage forms
Application:
12/380,642 →
Sustained Release Formulations of Nalbuphine
Application:
12/154,496 →
Sustained release formulations of oxymorphone
Application:
11/891,775 →
Sustained Release Matrix Systems for Highly Soluble Drugs
Application:
11/729,024 →
Methods for Treating Pain with Opioid Formulations Having Reduced Potential for Abuse
Application:
11/704,848 →
Robust sustained release formulations of oxymorphone
Application:
11/546,129 →
Robust sustained release formulations of oxymorphone and methods of use thereof
Application:
11/546,128 →
Robust sustained release formulations
Application:
11/545,954 →
Sustained release formulations of nalbuphine
Application:
11/509,347 →
Ethanol-resistant sustained release formulations
Application:
11/370,699 →
Chronotherapeutic Dosage Forms and Methods of Treatment Using Chronotherapy
Application:
11/001,675 →
Delayed Release Dosage Forms
Application:
10/943,356 →
Sustained Release Formulations of Metformin
Application:
10/630,239 →
Novel Once-a-Day Controlled Release Sulfonylurea Formulation
Application:
10/396,114 →
Opioid Formulations Having Reduced Potential for Abuse
Application:
10/254,207 →
Sustained Release Formulations of Oxymorphone
Application:
10/189,932 →
Controlled Release Insufflation Carrier for Medicaments
Application:
10/047,060 →
Sustained Release Heterodisperse Hydrogel Systems-Amorphous Drugs
Application:
09/879,296 →
Sustained Release Matrix for High-Dose Insoluble Drugs
Application:
09/842,289 →